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ABSTRACT
Globally, the issue of Multidrug Resistant Tuberculosis (MDR-TB) was 
acknowledged as a threat to the successful prevention and treatment of TB. In 
Malaysia, TB remains a major health issue and incidence has been rising slowly for 
the past decade indicating poor success rate in current TB control programme. 
Currently, very little epidemiological data can be found regarding the situation of TB 
and MDR-TB in Malaysia. Therefore, this study aims to bridge the gap in information 
regarding TB and MDR-TB by identifying the population at risk. The objective of this 
study is also to identify the independent risk factors associated with MDR-TB in 
Malaysia. 477 TB patients from the Institute of Respiratory Medicine (IPR) were 
universally sampled based on the records of patients in 2010. Among 477 patients 
sampled, 67.9% were male with mean age 37.2 (SD 14.9). 30% of patients were 
foreign born with the majority were from Myanmar (14.9%), Indonesia (9.4%) and 
Bangladesh (2.7%). Prevalence of TB/HIV and TB/Diabetes among the patients 
sampled was 0.059 and 0.155 respectively. In multivariate analysis, BCG Status 
(AOR=0.292, 95%CI 0.13-0.67) was found to be a protective risk factor while history 
of previous TB (AOR=4.36, 95%CI 1.80-10.56) was a risk factor for MDR-TB. 
Whilst history of previous TB is a commonly acknowledged risk factor, the evidence 
of BCG as a protective factor for MDR-TB indicates that BCG vaccination is still a 
viable preventive measure. Association was found between BCG Status and foreign 
bom patients (p-value <0.01) indicating a need for active screening of immigrants.
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CHAPTER ONE 
INTRODUCTION
1.1 INTRODUCTION
In the early 20th century, Tuberculosis (TB) was thought to have been almost 
eradicated thanks to the discovery of its treatment drugs. Yet, in 2010, the World 
Health Organization reported that approximately 8.8 million cases of TB were 
reported worldwide of which about 1.4 million resulted in mortality (WHO, 2011). It 
is clear that TB is still a threat and has caused a huge number of mortality now, and in 
the past.
Tuberculosis is a communicable disease caused by the bacterium 
Mycobacterium tuberculosis. The main target organ for this mycobacterium is the 
lungs. However, infections in other parts of the body are not uncommon. TB bacteria 
have been known to attack the kidney, spine and brain (CDC, 2010). The transmission 
of TB occurs in the air, hence it is known as an airborne disease. Mycobacterium 
tuberculosis can be transmitted during coughing, sneezing, speaking, thus infecting 
the people surrounding the patient.
The treatment of TB usually involves the injection of first-line and/or second- 
line of anti-tuberculosis drugs. Currently, the most common TB control and 
management programme is the Direct Observed Therapy, Short Course (DOTS) and 
so far, studies have indicated an increase in total success rate in the implementation of 
DOTS (Erhabor, et al., 2003; Woldeyohannes, et al., 2011).
However, poor management of TB control and treatment programme has 
resulted in the emergence of multi-drug resistance TB that threatens TB eradication 
programme (Sandhu, 2011). Resistance to an anti-tuberculosis drug occurs when 
Mycobacterium tuberculosis are able to withstand the attack of antibiotic (ALA, 
2011). Since drugs used are not able to eradicate the bacteria, resistance will spread 
from one person to another, resulting in a Drug-Resistance Tuberculosis (DR-TB). In 
fact, a study reported a mere 37.1% of success rate for 202 Multi-Drug Resistance TB 
(MDR-TB) patients in 3 different hospitals (Jeon, et al., 2011). Retreatment of the
